TAKE THIS POLL |
|
|
- FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia 19 Nov 2009 09:16 GMT
... VeriChip Corporation, a provider of radio frequency identification (RFID) systems for healthcare and... Human Genome Sciences, Inc. and ...
- BRIEF-Genentech and Biogen get FDA complete response for Rituxan in chronic lymphocytic leukemia 18 Nov 2009 22:39 GMT
... ...
- Facet Biotech Announces Four Presentations at American Society of Hematology Annual Meeting 19 Nov 2009 13:50 GMT
... Small Modular Immuno-Pharmaceutical (TruADhanCe(TM) SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells. Lead Investigator: Sarwish Rafiq, MD, Ohio State University Comprehensive Cancer Center When: Saturday, ...
- Facet Biotech Announces Four Presentations at American Society of Hematology 19 Nov 2009 14:15 GMT
... Small Modular Immuno-Pharmaceutical (TruADhanCe(TM) SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells. Lead Investigator: Sarwish Rafiq, MD, Ohio State University Comprehensive Cancer Center When: Saturday, ...
- Dr. Mark Weiss Joins the Department of Medical Oncology at Jefferson 17 Nov 2009 02:51 GMT
... at Jefferson, as he is internationally known for his work in hematologic malignancies, particularly chronic lymphocytic leukemia and acute lymphocytic leukemia." Dr. Weiss earned his Bachelor of Arts from Cornell University ...
- Reuters Health: Terra med Alliance News Green Tea Ingredient May Fight Incurable Leukemia 19 Nov 2009 02:31 GMT
... tea may shrink lymph nodes and reduce white blood cell counts in patients with chronic lymphocytic leukemia (CLL), a new study in the Journal of Clinical Oncology shows. Terra med Alliance ...
- Genentech, Biogen Idec Receive Complete Response from FDA for Rituxan for CLL 19 Nov 2009 13:58 GMT
... and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). Rituxan is a therapeutic antibody that binds to a specific protein called CD20 ...
- Genentech, Biogen Idec get FDA request on application for Rituxan's use in leukemia 18 Nov 2009 23:37 GMT
... for new data on the current application, which seeks approval as a treatment for chronic lymphocytic leukemia. It is the most common adult leukemia in the U.S. Genentech and Biogen said ...
- Discovery holds promise in fighting cancer, AIDS and autoimmune disorders 21 Nov 2009 08:13 GMT
... for nearly 30 years." To identify the true FCMR gene, the UAB researchers used chronic lymphocytic leukemia cells as a source of this gene, since such leukemia cells are known to ...
- Genentech and Biogen Receive FDA Letter Over Rituxan 20 Nov 2009 04:34 GMT
... for new data on the current application, which seeks approval as a treatment for chronic lymphocytic leukemia. It is the most common adult leukemia in the U.S. Genentech and Biogen said ...
- FDA Clears Way for Use of Rituxan for Leukemia 20 Nov 2009 06:58 GMT
... FDA has approved Genentech and Biogen Idec's Rituxan plus chemotherapy for patients with untreated chronic lymphocytic leukemia (CLL), opening up a new market for the pharmaceutical. This article is viewable by ...
- Genetic identity of cellular receptor for the immune system's first-response antibody discovered 19 Nov 2009 11:33 GMT
... for nearly 30 years." To identify the true FCMR gene, the UAB researchers used chronic lymphocytic leukemia cells as a source of this gene, since such leukemia cells are known to ...
- Genentech, Biogen get FDA request on Rituxan 18 Nov 2009 22:12 GMT
... for new data on the current application, which seeks approval as a treatment for chronic lymphocytic leukemia. It is the most common adult leukemia in the U.S. Genentech and Biogen said ...
- Lonza Successfully Develops A Manufacturing Process For Arzerra (Ofatumumab), A New Biopharmaceutical From GSK And Genmab 17 Nov 2009 06:51 GMT
... and Genmab's antibody Arzerra, which has just been approved for use in patients with chronic lymphocytic leukemia (CLL) by the US Food and Drug Administration (FDA), will be manufactured by Lonza. ...
- Antibody Receptor Identity Discovered 20 Nov 2009 21:56 GMT
... for nearly 30 years." To identify the true FCMR gene, the UAB researchers used chronic lymphocytic leukemia cells as a source of this gene, since such leukemia cells are known to ...
- Celgene and Innate Collaborate on Trial Combining Their Multiple Myeloma Therapies 18 Nov 2009 16:42 GMT
... dysplastic syndrome with deletion 5q. Additionally, the drug is in Phase III trials against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma as well as Phase II development against solid tumors. ...
- Researchers Discover Antibody Receptor Identity, Propose Renaming Immune-System Gene 18 Nov 2009 21:54 GMT
... for nearly 30 years." To identify the true FCMR gene, the UAB researchers used chronic lymphocytic leukemia cells as a source of this gene, since such leukemia cells are known to ...
- Genentech, Biogen Get FDA Request On Rituxan 18 Nov 2009 22:14 GMT
... for new data on the current application, which seeks approval as a treatment for chronic lymphocytic leukemia. It is the most common adult leukemia in the U.S. Genentech and Biogen said ...
- Stunts Raise Injury Risks for Cheerleaders 21 Nov 2009 15:33 GMT
... (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia. Twynsta (telmisartan/amlodipine) is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel ...
- When Sleep Suffers, So Does Decisiveness 21 Nov 2009 15:33 GMT
... (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia. Twynsta (telmisartan/amlodipine) is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel ...
1 - 25 of 180 next >
Powered by 
News by PR Newswire
24-7 pressrelease
Emailwire
|
a digital news provider
